

CLAIMS

1. Use of compound A in the manufacture of a pharmaceutical composition for treating insomnia, wherein a therapeutically effective amount of compound A is to be administered orally in a single daily dose ranging from 2.5 mg to 10 mg, wherein said single daily dose achieves a mean Cmax of 3.0 ng/ml to 7.2 ng/ml for each 1 mg of compound A after administration to human subjects, and wherein said compound A is (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide represented by a following formula:



2. Use of compound A in the manufacture of a pharmaceutical composition for treating insomnia comprising a therapeutically effective amount of compound A and at least one pharmaceutically acceptable excipient, wherein compound A is to be administered orally, wherein said therapeutically effective amount is a single daily dose ranging from 2.5 mg to 10 mg, wherein said single daily dose achieves a mean Cmax of 3.0 ng/ml to 7.2 ng/ml for each 1 mg of compound A after administration to human subjects, and said compound A is (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide represented by a following formula:



3. The use of claim 2, wherein said therapeutically effective amount is a single 5 mg daily dose, and wherein said single 5 mg dose achieves a mean Cmax within the range of 80% to 125% of 23 ng/ml, or said therapeutically effective amount is a single 10 mg daily dose, and wherein said single 10 mg daily dose achieves a mean Cmax within the range of 80% to 125% of 36 ng/ml.

4. The use of claim 2, wherein said therapeutically effective amount is a single daily dose to achieve a mean AUC(0-24) of 15.9 ng*hr/ml to 23.8 ng*hr/ml for each 1 mg of compound A.

5. The use of claim 2, wherein said therapeutically effective amount is a single 5 mg daily dose, and wherein said 5 mg single daily dose achieves a mean AUC(0-24) within the range of 80% to 125% of 95 ng*hr/ml, or said therapeutically effective amount is a single 10 mg daily dose, and wherein said single 10 mg daily dose achieves a mean AUC(0-24) within the range of 80% to 125% of 159 ng*hr/ml.

6. The use of claim 2, wherein said therapeutically effective amount is a single daily dose to achieve a mean AUC(0-t) of 19.1 ng*hr/ml to 51.1 ng*hr/ml for each 1 mg of compound A.

7. The use of claim 2, wherein said therapeutically effective amount is a single 5 mg daily dose, and wherein said single 5 mg daily dose achieves a mean AUC(0-t) within the range of 80% to 125% of 128 ng*hr/ml or said therapeutically effective amount is a single 10 mg daily dose, and wherein said single 10 mg daily dose achieves a mean AUC(0-t) within the range of 80% to 125% of 284 ng*hr/ml.

8. The use of claim 2, wherein said therapeutically effective amount is a single daily dose to achieve a mean AUC(0-inf) of 19.8 ng*hr/ml to 53.1 ng*hr/ml for each 1 mg of compound A.

9. The use of claim 2, wherein said therapeutically effective amount is a single 5 mg daily dose, and wherein said single 5 mg daily dose achieves a mean AUC(0-inf) within the range of 80% to 125% of 149 ng*hr/ml or said therapeutically effective amount is a single 10 mg daily dose, and wherein said single 10 mg daily dose achieves a mean AUC(0-inf) within the range of 80% to 125% of 311 ng*hr/ml.

10. The use of claim 2, wherein said daily dose provides a mean plasma compound A concentration of about 20 ng/ml or less at from 8 to 10 hours after single dose administration to human subjects.